The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
11 (2024): e086424, 10.1136/bmjopen-2024-086424
My wife and friends certainly seem to stand by its hangover easing/reducing efficacy
[22] [23] By activating GLP-1 receptors, these medications enhance insulin secretion when blood glucose levels are elevated, suppress glucagon release, slow gastric emptying, and promote satiety
Supplementary material The Supplementary Material for this article can be found online at: References 1 AdhikariL.BaralR.PaudelD
Common formulations include 10mg, 12mg, 15mg, or 20mg per vial